
    
      The drug being tested in this study is called trebananib (AMG 386). Trebananib (AMG 386) is
      being tested to treat people with advanced solid tumors.

      This study will look at the safety, tolerability and pharmacokinetic (PK) profile of
      trebananib and response to treatment.

      The study will enroll approximately 18 participants. Once enrolled, participants will be
      assigned sequentially into 1 of the 3 cohorts:

        -  Trebananib 3 milligram/kilogram (mg/kg),

        -  Trebananib 10 mg/kg,

        -  Trebananib 30 mg/kg.

      All participants will receive trebananib via 60 minute intravenous infusion. This study will
      be conducted in Japan. The overall time to participate in this study is 14 weeks or more.
      Participants will attend the end-of-treatment visit 28 days after the last dose of study
      drug.
    
  